SynthesisPharmacogenomics2017
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.
Synthesis in Pharmacogenomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information.Clinical pharmacology and therapeutics · 2025Article
- Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago.Cardiology and therapy · 2024Article
- Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia.Human genetics · 2024Article
- Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?Clinical and translational science · 2023Review
- Editorial: The role of pharmacogenomics in addressing health disparities: the path, the promise, and the barriers.Frontiers in genetics · 2023Article
- The pursuit of health equity in digital transformation, health informatics, and the cardiovascular learning healthcare system.American heart journal plus : cardiology research and practice · 2022Article
- Recent advances in pharmacogenomics research of anti-asthmatic drugs: a narrative review.Annals of translational medicine · 2022Review
- Ethnic Diversity and Warfarin Pharmacogenomics.Frontiers in pharmacology · 2022Review
- Health equality, race and pharmacogenomics.British journal of clinical pharmacology · 2022Review
- Cardio oncology: Digital innovations, precision medicine and health equity.Frontiers in cardiovascular medicine · 2022Review
- Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.Frontiers in genetics · 2022Article
- Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients.Journal of personalized medicine · 2021Article
- Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a NewFrontiers in psychiatry · 2021Article
- Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients.Pharmacogenomics and personalized medicine · 2021Article
- Why African Americans say "No": A Study of Pharmacogenomic Research Participation.Ethnicity & disease · 2020Article
- International Society of Psychiatric Genetics Ethics Committee: Issues facing us.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2019Review
- Implementation of clinical pharmacogenetic testing in medically underserved patients: a narrative review.PharmacogenomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This review assessed evidence of disparities in benefits of pharmacogenomics related to 'model performance' in subgroups of patients and studies which reported impact on health inequalities. 'Model performance' refers to the ability of algorithms including clinical, environmental and genetic information to guide treatment. A total of 4978 abstracts were screened by one reviewer and 30% (1494) were double screened by a second independent reviewer, after which data extraction was performed. Additional forward and backward citation searching of reference lists was conducted. Investigators independently double rated study quality and applicability of included studies. Only five individual studies were identified which met our inclusion criteria, but were contradictory in their conclusions. While three studies of genotype-guided dosing of warfarin reported that ethnic disparities in healthcare may widen, two other studies (one reporting on warfarin and reporting on clopidogrel) suggested that disparities in healthcare may reduce. There is a paucity of studies which evaluates the impact of pharmacogenomics on health disparities. Further work is required not only to evaluate health disparities between ethnic groups and countries but also within ethnic groups in the same country and solutions need to be identified to overcome these disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.